Morgan Stanley Downgrades MapLight Therapeutics to Equal-Weight, Lowers Price Target to $21

Benzinga Newsdesk www.benzinga.com Negative 92.6%

Neg 92.6% Neu 0% Pos 0%

Morgan Stanley analyst Sean Laaman downgrades MapLight Therapeutics (NASDAQ:MPLT) from Overweight to Equal-Weight and lowers the price target from $34 to $21.